BioSpace News Archive

ViaCyte, Inc. announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021 , at 10:15 a.m. PT in Carlsbad, CA.

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, announced the appointment of Doug Schenkel as Chief Financial Officer.

StageZero Life Sciences, Ltd. announced today that patients in Virginia and the Washington, D.C. metropolitan area (D.C., Md., Va.) can now directly access Aristotle™, the company’s multi-cancer blood test, via its Richmond, Va. laboratory.

Recursion today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer who received the drug prior to each chemotherapy treatment had significantly lower use of supportive care therapies for chemotherapy-induced myelosuppression than patients who received placebo.

NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, today announced that Stephen Chen, NKGen Biotech’s Chief Technical Officer, will present at the Virtual Solebury Trout Fall Private Company Showcase.

BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first cross-over patient in the ongoing Phase III Pivotal CardiAMP® Cell Therapy in Heart Failure Trial for the treatment of ischemic heart failure.

SCYNEXIS, Inc. today announced two poster presentations of interim data from its ongoing FURI and CARES studies, evaluating oral ibrexafungerp for the treatment of patients with refractory mucocutaneous and invasive fungal infections will be presented at the 10th Trends in Medical Mycology (TIMM) Meeting

Pliant Therapeutics, Inc. today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m. ET.

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient has been dosed in the Phase 1/2 study in Canada with three other patients enrolled and scheduled to begin dosing.